The availability of antibodies against the target antigen can be determined at a glance!
We have established a healthy human antibody library from the culture supernatants of LCL derived from antibody-producing cells (including memory B cells) using the EBV method. The library is composed of samples from 100 donors, created from mononuclear cells isolated from 100 to 200 ml of blood per person. By using human peripheral blood lymphocytes (PBMC) collected from various ethnicities around the world, we can explore the feasibility of obtaining human antibodies against specific antigens. 【Features】 ■ Composed of 100 donors ■ Created from mononuclear cells isolated from 100 to 200 ml of blood per person ■ Immediate checks can be made to determine which donors are suitable for antibody production *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
**Overview** The human healthy donor antibody library consists of 100 donors, with mononuclear cells isolated from 100 to 200 ml of blood per person. By examining whether the desired antibodies survive in the LCL culture supernatants of each donor, we can quickly check which donor is suitable for antibody production. This system allows for the efficient cloning of antibody genes against the target antigen from promising samples. *For more details, please refer to the catalog or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
iBeck Co., Ltd. is a company engaged in the manufacturing and sales of fully human antibodies for pharmaceuticals. By utilizing a unique method that does not rely on patents from Europe and the United States, we are able to produce fully human antibodies with fewer side effects. We have developed a technology to produce fully human antibodies from blood B lymphocytes, which are responsible for antibody production in the human body. Additionally, we provide these antibodies to companies involved in antibody pharmaceuticals and engage in joint development as alliance partners.
